|
**Overview**: Grow Indigo Female Radiology Panel**Introduction**: The Grow Indigo Female Radiology Panel is a comprehensive health screening tool designed for adult females using serum and radiology assessments. In India, preventive health checkups for women are underutilized (~20-30 percent uptake in urban areas, lower in rural/low-SES), missing early detection of diabetes, dyslipidemia, thyroid disorders, breast/cervical cancer, and cardiovascular risk. High burden from delayed screening leading to advanced disease presentation. Per preventive medicine practices aligned with ICMR and NPCDCS guidelines, the panel combines biochemistry (fasting glucose, lipids, creatinine, TSH, CBC) and radiology (chest X-ray, ECG, mammography, Pap smear) over 1-2 days, valuable for routine female health evaluation. This diagnostic falls under general health routine and targets adult women (>30 years), addressing accurate detection to guide lifestyle modification, vaccination, or referral. With elevated morbidity due to under-screening, the test supports public health efforts by enabling comprehensive assessment and reducing NCD burden. Its multi-modal approach ensures reliable screening.**Other Names**: Indigo Female Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/radiology, compliant with 2025 standards.**Historical Milestone**: Comprehensive female screening; in India, adopted in corporate/wellness programs.**Purpose**: The test assesses 9 parameters including fasting glucose to guide general female health screening, detect metabolic/cancer risk, inform prevention.**Test Parameters**: 1. Fasting Glucose, 2. Total Cholesterol, 3. Creatinine, 4. TSH, 5. CBC, 6. Chest X-Ray, 7. ECG, 8. Mammography, 9. Pap Smear.**Pretest Condition**: Fasting 10-12 hours required; patients should be adult females.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on age, menstrual history, family cancer.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected conditions including cancer, benefits of screening, and minimal discomfort from blood/radiology.**Procedural Considerations**: The test involves sample processing using spectrophotometry/radiology by trained personnel to ensure sterile technique and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or non-fasting can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate risk, necessitating specialist input.**Specialist Consultation**: Physicians or gynecologists should be consulted for management.**Additional Supporting Tests**: Ultrasound breast, lipid profile details for confirmation.**Test Limitations**: Age-appropriate; comprehensive approach required.**References**: Indian Journal of Community Medicine 2024, Screening Studies India 2023. |
